Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D
Zhongjuan Wang, Linghua Guo, Yuan Song, et al.
Cancer Immunology Immunotherapy (2017) Vol. 66, Iss. 4, pp. 537-548
Closed Access | Times Cited: 69

Showing 26-50 of 69 citing articles:

NK Cell Metabolism and TGFβ – Implications for Immunotherapy
Karen Slattery, Clair M. Gardiner
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 43
Regulatory T-cell therapy approaches
Oliver McCallion, Merve Bilici, Joanna Hester, et al.
Clinical & Experimental Immunology (2022) Vol. 211, Iss. 2, pp. 96-107
Open Access | Times Cited: 26
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
Ali Keshavarz, Ali Salehi, Setareh Khosravi, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 24
The application of autologous cancer immunotherapies in the age of memory-NK cells
Gaby D. Lizana‐Vasquez, Madeline Torres‐Lugo, R. Brent Dixon, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy
Ramona Rotolo, Valeria Leuci, Chiara Donini, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 11, pp. 2839-2839
Open Access | Times Cited: 42
Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells
Changjiang Guo, Xiaoyin Wang, Huiyong Zhang, et al.
Molecular Immunology (2019) Vol. 114, pp. 108-113
Closed Access | Times Cited: 38
Next Generation Natural Killer Cells for Cancer Immunotherapy
Fiorella Rossi, Nathaniel Fredericks, Andrew Snowden, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Natural killer cell therapy: A new frontier for obesity-associated cancer
Eimear Mylod, Joanne Lysaght, Melissa J. Conroy
Cancer Letters (2022) Vol. 535, pp. 215620-215620
Open Access | Times Cited: 21
Optimizing glutamine concentration enhances ex vivo expansion of natural killer cells through improved redox status
Danni Ying, Guofeng Zhang, Huimin Huang, et al.
Biotechnology Progress (2024) Vol. 40, Iss. 4
Closed Access | Times Cited: 4
Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race
Dennis Christoph Harrer, Jan Dörrie, Niels Schaft
Human Gene Therapy (2018) Vol. 29, Iss. 5, pp. 547-558
Closed Access | Times Cited: 37
Functional and metabolic targeting of natural killer cells to solid tumors
Jiao Wang, Sandro Matosevic
Cellular Oncology (2020) Vol. 43, Iss. 4, pp. 577-600
Closed Access | Times Cited: 30
Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy
Yuanlin Wu, Jing Li, Parham Jabbarzadeh Kaboli, et al.
Pharmacological Research (2020) Vol. 155, pp. 104691-104691
Closed Access | Times Cited: 28
Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment
Natasha Mupeta Kaweme, Fuling Zhou
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 24
CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges
Ayda Baghery Saghchy Khorasani, Amir‐Mohammad Yousefi, Davood Bashash
International Immunopharmacology (2022) Vol. 110, pp. 109041-109041
Closed Access | Times Cited: 18
Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics
Kassandra Coyle, Lindsey G. Hawke, Mark L. Ormiston
Cancers (2023) Vol. 15, Iss. 6, pp. 1743-1743
Open Access | Times Cited: 10
Natural killer cell-based cancer immunotherapy: from basics to clinical trials
Ying‐Hong Shi, Donglin Hao, Hui Qian, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment
Ishwar Navin, Michael T. Lam, Robin Parihar
Cancers (2020) Vol. 12, Iss. 12, pp. 3871-3871
Open Access | Times Cited: 27
Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function
Simone Mantesso, Dirk Geerts, Jan Spanholtz, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 25
T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer
Vasyl Eisenberg, Shiran Hoogi, Astar Shamul, et al.
Advanced Drug Delivery Reviews (2019) Vol. 141, pp. 23-40
Closed Access | Times Cited: 24
Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
Dayane Schmidt, Sima Ebrahimabadi, Kauan Ribeiro de Sena Gomes, et al.
Immunotherapy Advances (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 13
Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors
Abdolreza Esmaeilzadeh, Kaveh Hadiloo, Marjan Jabbari, et al.
Life Sciences (2023) Vol. 337, pp. 122381-122381
Closed Access | Times Cited: 7
Challenges and opportunities for cancer stem cell‐targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell‐dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes
Abdullah Alqarni, Saade Abdalkareem Jasim, Farag M. A. Altalbawy, et al.
Journal of Biochemical and Molecular Toxicology (2024) Vol. 38, Iss. 6
Closed Access | Times Cited: 2
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
Minggang Fang, Alexander G. Allen, Chong Luo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
NK-92 cell, Another Ideal Carrier for Chimeric Antigen Receptor
Wanning Wang, Guangyu Zhou, Wenlong Zhang
Immunotherapy (2017) Vol. 9, Iss. 9, pp. 753-765
Closed Access | Times Cited: 20
Roles of innate lymphoid cells in metabolic and alcohol-associated liver diseases
Manon Bourinet, Rodolphe Anty, Philippe Gual, et al.
JHEP Reports (2023) Vol. 6, Iss. 2, pp. 100962-100962
Open Access | Times Cited: 6

Scroll to top